1. Home
  2. Labeler Index
  3. Bluebird Bio, Inc.
  4. NDC Product Code: 73554-2111 Skysona

NDC 73554-2111 Skysona

Elivaldogene Autotemcel Suspension Intravenous - View Dosage, Usage, Ingredients, Routes, UNII

Table of Contents

  1. Product Information
  2. Product Packages
  3. What is NDC 73554-2111?
  4. Skysona Uses
  5. Active Ingredients
  6. Active Ingredients UNII Codes
  7. NDC to RxNorm Crosswalk
  8. Patient Education

Product Information

NDC Product Code:
73554-2111
Proprietary Name:
Skysona
Non-Proprietary Name: [1]
Elivaldogene Autotemcel
Substance Name: [2]
Elivaldogene Autotemcel
NDC Directory Status:
Cellular Therapy
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Dosage Form:
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route(s): [4]
  • Intravenous - Administration within or into a vein or veins.
    • Labeler Name: [5]
    Bluebird Bio, Inc.
    Labeler Code:
    73554
    Product Label ID:
    f189502b-dc44-4289-99a6-cfba36918329
    FDA Application Number: [6]
    BLA125755
    Marketing Category: [8]
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date: [9]
    09-16-2022
    Listing Expiration Date: [11]
    12-31-2024
    Exclude Flag: [12]
    N
    Code Navigator:

    Code Structure Chart

    Product Details

    What is NDC 73554-2111?

    The NDC code 73554-2111 is assigned by the FDA to the product Skysona which is a cellular therapy product labeled by Bluebird Bio, Inc.. The generic name of Skysona is elivaldogene autotemcel. The product's dosage form is suspension and is administered via intravenous form. The product is distributed in a single package with assigned NDC code 73554-2111-1 1 suspension in 1 bag . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

    What are the uses for Skysona?

    SKYSONA is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Early, active cerebral adrenoleukodystrophy refers to asymptomatic or mildly symptomatic (neurologic function score, NFS ≤ 1) boys who have gadolinium enhancement on brain magnetic resonance imaging (MRI) and Loes scores of 0.5-9.This indication is approved under accelerated approval based on 24-month Major Functional Disability (MFD)-free survival [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

    What are Skysona Active Ingredients?

    An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.

    Which are Skysona UNII Codes?

    The UNII codes for the active ingredients in this product are:

    • ELIVALDOGENE AUTOTEMCEL (UNII: KUM75TD6SG)
    • ELIVALDOGENE AUTOTEMCEL (UNII: KUM75TD6SG) (Active Moiety)

    What is the NDC to RxNorm Crosswalk for Skysona?

    RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
    • RxCUI: 2612552 - elivaldogene autotemcel 30,000,000 CELLS/mL in 20 ML Injection
    • RxCUI: 2612552 - 20 ML elivaldogene autotemcel 30000000 CELLS/ML Injection
    • RxCUI: 2612552 - elivaldogene autotemcel 30,000,000 CELLS/ML per 20 ML Injection
    • RxCUI: 2612558 - skysona 30,000,000 CELLS/mL in 20 ML Injection
    • RxCUI: 2612558 - 20 ML elivaldogene autotemcel 30000000 CELLS/ML Injection [Skysona]

    * Please review the disclaimer below.

    Patient Education

    Elivaldogene autotemcel Injection


    Elivaldogene autotemcel injection is used to slow the progression of brain damage and slow the decline of nerve function in males 4–17 years of age with early, active cerebral adrenoleukodystrophy (CALD; an inherited condition in which fatty acids build up in the brain, resulting in nerve and brain damage). Elivaldogene autotemcel injection is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by helping your body to break down the fatty acids and slow the progression of nerve and brain damage.
    [Learn More]


    * Please review the disclaimer below.

    Product Footnotes

    [1] What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

    [2] What is the Substance Name? - An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.

    [3] What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

    [4] What are the Administration Routes? - The translation of the route code submitted by the firm, indicating route of administration.

    [5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

    [6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

    [8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

    [9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

    [11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

    [12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".